American Tungsten & Antimony Managing Director Andre Booyzen says the Company’s maiden drilling at Utah’s Antimony Canyon has confirmed a thick, laterally continuous stibnite system with geological vectoring pointing toward a high priority feeder structure.
Lunnon Metals Managing Director Edmund Ainscough says down plunge drilling at Lady Herial confirms high grade continuity beyond the current open pit.
Managing Director Matt Szwedzicki says West Cobar Metals’ portfolio aligns directly with Australia’s Critical Minerals Strategic Reserve priorities.
Dundas Minerals has secured an 80% stake in the Romano Project, adding a ~800 km² frontier gold position in the north eastern Goldfields of Western Australia adjacent to the Gruyere gold mine, one of the state’s most recent major gold discoveries.
Daniel Tuffin, Executive Technical Director and Chief Executive Officer of Cavalier Resources, says recent high grade results south of the Crawford Stage 1 starter pit reinforce mineralisation continuity and support progression toward an updated Mineral Resource Estimate.
American Uranium Limited (ASX: AMU) Chief Executive Officer and Executive Director Bruce Lane chatted to MarketOpen on how recent drilling at Lo Herma confirmed uranium mineralisation extending well beyond the current mine unit footprint.
Lyle Thorne outlines how disciplined exploration across Diablo Resources’ Utah projects is sharpening targets and setting up the next phase of technical decision making.
Exploration outcomes at the Rae Copper Project have strengthened confidence in mineral system scale, with White Cliff Minerals Managing Director Troy Whittaker providing perspective on the geological framework.
Viking Mines Managing Director and CEO Julian Woodcock outlines a strategic expansion into US critical minerals as the company secures a portfolio of high grade, production proven tungsten projects in Nevada amid tightening global supply.
Dr Liz Dallimore, Managing Director of Argenica Therapeutics, spoke to MarketOpen about how an AI enabled reanalysis of the Phase 2 trial has clarified ARG 007’s efficacy in patients with severe acute ischaemic stroke.